| 000 | 01493 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250515031158.0 | ||
| 264 | 0 | _c20060731 | |
| 008 | 200607s 0 0 eng d | ||
| 022 | _a1352-4585 | ||
| 024 | 7 |
_a10.1191/135248506ms1261oa _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGottesman, M H | |
| 245 | 0 | 0 |
_aInterferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS). _h[electronic resource] |
| 260 |
_bMultiple sclerosis (Houndmills, Basingstoke, England) _cJun 2006 |
||
| 300 |
_a271-80 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aInterferon beta-1b |
| 650 | 0 | 4 |
_aInterferon-beta _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Chronic Progressive _xdrug therapy |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 | _aNeutralization Tests |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aFriedman-Urevich, S | |
| 773 | 0 |
_tMultiple sclerosis (Houndmills, Basingstoke, England) _gvol. 12 _gno. 3 _gp. 271-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1191/135248506ms1261oa _zAvailable from publisher's website |
| 999 |
_c16359983 _d16359983 |
||